Clinical Research Directory
Browse clinical research sites, groups, and studies.
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Summary
The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.
Official title: Phase II Clinical Study to Evaluate the Efficacy and Safety of Teniposide as a Post-Line Therapy for c-Myc-Driven Extensive-Stage Small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2025-02-07
Completion Date
2026-12-31
Last Updated
2025-12-05
Healthy Volunteers
No
Conditions
Interventions
Teniposide administration
Teniposide administration: 60mg/m2, diluted with 500ml of 0.9% sodium chloride injection before use, intravenous infusion for more than 1 hour, for 3-5 consecutive days, with 21 days as one cycle of treatment.
Locations (1)
Shanghai Pulmonary Hospital, Shanghai, China
Shanghai, Shanghai Municipality, China